FDA Expedited IND Pilot Tests Rolling Review for First-in-Human Trials

Drug developers who want to take a new molecule into its first human study in the United States have until 11:59 pm Eastern on 30 October 2026 to apply for the FDA's Expedited Investigational New Drug (IND) Pilot Program. The pilot changes when and how the agency looks at a first-in-human application. Instead of receiving one finished package, FDA reviewers would see the nonclinical, manufacturing and clinical sections one at a time as they are completed. Each sponsor would also work with an outside "qualified research institution" (QRI) that advises on the dossier before it reaches the agency.

FDA opened the application window on 15 September and says it plans to select the cohort and notify all applicants by 18 December, although the timeline may slip if many applications arrive. Trade press reports put the expected cohort at eight to 10 sponsor and QRI pairs, a figure FDA gave when it announced the pilot. The program's own web page does not state a number. The pilot is voluntary and is the main FDA element of Operation TrialBlazer, a Department of Health and Human Services effort launched in June 2026 to keep more early-stage clinical research in the United States.

The problem the pilot is aimed at

An IND is the application a sponsor must have in effect before giving an unapproved drug to people. Under 21 CFR 312.40(b), a study may begin 30 days after FDA receives the IND unless the agency places it on clinical hold, or sooner if FDA says it is safe to proceed. That 30-day clock is short, and the pilot does not change it. The delays that worry policymakers mostly happen before and around it: assembling the toxicology, pharmacology and chemistry, manufacturing and controls (CMC) data; finding out late that a section is not adequate for a first-in-human dose; and then activating trial sites and obtaining institutional review board (IRB) approval one step after another.

FDA has said that getting a first-in-human trial under way in the United States can take up to two years, and it compares that with faster start-up in China and Australia. Australia has no IND equivalent for early-phase work, relying on a notification scheme overseen by ethics committees, and China has combined faster regulatory timelines with cost advantages and large patient populations. Industry analysts quoted in the trade press see the expedited IND route as the most practical part of Operation TrialBlazer, while noting that those structural advantages abroad will not disappear because of a review pilot.

How the pilot works

Rolling review of IND components

Rolling review is familiar from marketing applications. Sponsors with Fast Track designation, for example, can submit completed sections of a new drug or biologics license application before the rest is ready. The pilot applies the same idea earlier, at the IND stage. FDA will accept and review individual components, such as the pharmacology and toxicology package, the CMC section or the clinical protocol, as each is finished. The stated aim is to find and fix deficiencies in real time, so that a sponsor is less likely to meet a clinical hold or a long list of information requests once the full IND is in.

Sponsors keep ownership of and responsibility for every component they submit. Applications to join may be filed in non-eCTD format, but selected sponsors must send their later rolling components in eCTD format.

The qualified research institution

The novel element is the QRI. FDA's page lists academic medical centers, health networks, contract research organizations, regulatory advisory firms and other research organizations as possible QRIs. Their job is to advise the sponsor on the nonclinical, CMC and clinical parts of the IND and to support coordination of IRB review and site activation alongside the regulatory work, so those steps run in parallel rather than in sequence.

The final design settles how the partnership is formed. FDA does not assign institutions: the sponsor must find its own partner, each application may name only one QRI, and the pair applies together through FDA's Electronic Submissions Gateway. FDA evaluates the two parties as a single package. A sponsor needs a pre-submission tracking number but does not need to have held a pre-IND meeting.

To be prioritized, a QRI must be a legal entity organized in the United States with its principal place of business and core advisory staff there. It must commit to supporting the IND across the nonclinical, CMC and clinical disciplines, and to running Phase 1 trials in the United States through infrastructure it owns or formal partnerships. FDA will look for documented experience in clinical pharmacology, regulatory affairs and Phase 1 trial support, and QRIs may bring in outside experts to fill gaps.

Which programs are eligible

The pilot covers commercial INDs for a Phase 1 first-in-human trial to be conducted in the United States, for novel products reviewed by CDER's Office of New Drugs, CBER's Office of Therapeutic Products or the Oncology Center of Excellence. Priority goes to new molecular entities without prior clinical experience. New formulations, delivery systems, drug-device combinations, new routes or dosage forms, and 505(b)(2) programs are not the main focus. Novel platforms are not excluded, but support is limited to the technology as used in the specific IND.

Selection will weigh how complex the IND is and how well it suits rolling review; whether the program is advanced enough to submit credibly but early enough for the QRI's input to matter; public health impact and unmet need; the sponsor's size and IND experience; and the diversity of the cohort, including rare diseases, pediatric indications and novel modalities. FDA says that not being selected "will not disadvantage sponsors in any way."

What FDA keeps, and how conflicts are handled

FDA is explicit that the QRI is an advisory resource, not a delegated reviewer. The agency retains full regulatory authority, including the decisions on whether an investigation may proceed and whether to impose a clinical hold, and it says participation does not change the statutory or regulatory standards for an IND. Every submission still receives an independent FDA review.

Conflict of interest was one of the main questions in the request for information, because a QRI could plausibly be paid by the sponsor, run the trial site and host the IRB. The final terms leave sponsors and QRIs to identify and manage their own conflicts, with written procedures available to FDA on request. If a conflict compromises a QRI's objectivity, the pair is removed from the pilot. Where a QRI owns or operates the IRB that will review the protocol, IRB members may not also serve in the pilot's advisory process, and that separation must hold for the whole pilot.

Related policy moves

The pilot sits alongside other FDA actions aimed at early development. The agency has launched a Phase 1 IND Navigator web page and a Phase 1 contact center, and has updated its guidance on phase-appropriate CMC requirements for first-in-human INDs for CDER-regulated drugs. FDA says that CMC clarification alone can save companies 6 to 12 months of development time. That estimate refers to the CMC update, not to the pilot, whose benefit has not yet been measured.

Separately, the proposed PDUFA VIII package discussed at FDA's 16 September public meeting includes a 50% reduction in the application fee for marketing applications containing data from at least one Phase 1 trial anchored in the United States and started after 1 October 2027. That is a proposal. It depends on user-fee reauthorization by Congress before the current agreement expires on 30 September 2027.

Limitations and open questions

• Small scale. A cohort of around eight to 10 programs can show whether the model is workable, but it is too small to show a reliable change in clinical hold rates or start-up times across the industry.
• No published metrics. FDA lists the outcomes it will assess: better phase-appropriate data, earlier resolution of problems, fewer Phase 1 holds and information requests, faster progress to first-in-human dosing and better coordination of trial start-up. It has not published quantitative targets or a defined pilot duration.
• Agency workload. Rolling review asks reviewers to engage repeatedly with partial dossiers. Whether that fits within current staffing, and how it would scale beyond a pilot, is not addressed on the program page.
• Independence of advisers. Self-managed conflict-of-interest procedures put a lot of weight on QRI governance. Commentators on the June proposal also raised questions about liability, the legal basis for relying on third-party advisers, and how disagreements between a QRI and FDA would be settled.
• Access for smaller sponsors. Because sponsors must bring their own QRI, companies without existing academic or CRO relationships may find it harder to apply within the window.

What to watch

The next markers are the 30 October deadline and the cohort announcement expected around 18 December. After that, the questions are whether FDA reports how many applications it received, what kinds of products and institutions were chosen, and whether early participants see fewer holds or faster site activation than comparable programs. FDA has said the pilot may inform future approaches such as certification or accreditation of QRIs. A formal accreditation scheme would be a larger structural change to how first-in-human applications are prepared in the United States, and would probably need its own public process.

This article is for information only and is not medical advice. Treatment decisions should be made with a qualified clinician.

Sources: U.S. FDA, Expedited IND Pilot Program; U.S. FDA, Actions to Accelerate Clinical Development; Clinical Trials Arena; Targeted Oncology; Arnold & Porter; U.S. FDA, PDUFA public meeting